Attached files
| file | filename |
|---|---|
| EX-99.1 - PAR PHARMACEUTICAL COMPANIES, INC. | v207913_ex99-1.htm |
SECURITIES AND EXCHANGE
COMMISSION
Washington,
DC 20549
______________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): January 12,
2011
PAR
PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
|
File
Number 1-10827
|
22-3122182
|
|
(State
or other jurisdiction of
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
|
Identification
No.)
|
| 300 Tice Boulevard, Woodcliff Lake, NJ |
07677
|
|
| (Address of principal executive offices) |
(Zip Code)
|
Registrant’s
telephone number, including area code: (201) 802-4000
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02. Results of Operations and
Financial Condition.
On
January 12, 2011, Par Pharmaceutical Companies, Inc. (the “Company”) presented
an overview of the Company’s growth strategy and its three-year financial
outlook at the 29th Annual
J.P. Morgan Healthcare Conference in San Francisco, California. A
copy of the power point presentation from the J.P. Morgan Healthcare Conference
is set forth in Exhibit 99.1 attached hereto.
The
information in this Current Report on Form 8-K, including Exhibit 99.1, is
furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such
filing.
Item
9.01 Financial
Statements and Exhibits.
|
(d)
|
The
following exhibit is furnished with this Current Report on Form
8-K:
|
|
Exhibit
No.
|
Description
|
|
|
99.1
|
29th
Annual J.P. Morgan Healthcare Conference presentation of January 12,
2011
|
Certain
statements in this Current Report on Form 8-K constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. To the extent that any statements made in this Current Report on Form
8-K contain information that is not historical, such statements are essentially
forward-looking and are subject to certain risks and uncertainties, including
the risks and uncertainties discussed from time to time in the Company’s filings
with the SEC, including its Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements
included in this Current Report on Form 8-K are made as of the date hereof only,
based on information available to the Company as of the date hereof, and,
subject to any applicable law to the contrary, the Company assumes no obligation
to update any forward-looking statements.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Dated as
of: January 12, 2011
| PAR PHARMACEUTICAL COMPANIES, INC. | |||
|
(Registrant)
|
|||
|
/s/ Thomas J.
Haughey
Thomas
J. Haughey, Executive Vice President, Chief
Administrative
Officer and General Counsel
|
|||
3